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Chronic liver inflammation and hepatocellular carcinoma:
persistence matters
Abstract
Inflammatory responses in the liver--a central constituent of hepatic wound healing--can be
self-limited or persistent depending on the aetiology, liver health state, concentration of toxins
or pathogens, and the time frame of exposure to toxins or infection. In case the immune system
eradicates a pathogen or in case toxin-exposure is transient, acute hepatitis resolves and the
affected liver tissue regenerates ad integrum. However, in many cases liver damage remains
chronic. Irrespective of the aetiology, chronic liver damage drives chronic hepatitis and
hepatocyte death as well as compensatory proliferation, reflecting liver regeneration. Over
time this potentially promotes further hepatic damage, fibrosis, cirrhosis and liver cancer.
Here, we review the current knowledge on how chronic liver injury and inflammation is
triggered and maintained, and how inflammation is linked to liver cancer. We also discuss the
most frequently used animal models for damage or inflammation induced liver cancer and
their suitability for conducting clinically relevant research.
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Summary
Inflammatory responses in the liver – a central constituent
of hepatic wound healing – can be self-limited or persistent
depending on the aetiology, liver health state, concentration
of toxins or pathogens, and the time frame of exposure to
toxins or infection. In case the immune system eradicates a
pathogen or in case toxin-exposure is transient, acute hep-
atitis resolves and the affected liver tissue regenerates ad
integrum. However, in many cases liver damage remains
chronic. Irrespective of the aetiology, chronic liver dam-
age drives chronic hepatitis and hepatocyte death as well as
compensatory proliferation, reflecting liver regeneration.
Over time this potentially promotes further hepatic dam-
age, fibrosis, cirrhosis and liver cancer. Here, we review
the current knowledge on how chronic liver injury and in-
flammation is triggered and maintained, and how inflam-
mation is linked to liver cancer. We also discuss the most
frequently used animal models for damage or inflamma-
tion induced liver cancer and their suitability for conduct-
ing clinically relevant research.
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Acute and chronic hepatitis –inflammation of the liver
The term hepatitis (i.e. inflammation of the liver) desig-
nates a broad spectrum of diseases. The clinical course of
hepatitis ranges from no or only limited symptoms, clinic-
al appearance characterised by poor appetite, malaise and
jaundice to fulminant liver failure [1]. Hepatitis can be self-
limited or persistent. The terms acute and chronic hepatit-
is are defined by the duration of disease with less or more
than six months, respectively. The spectrum of aetiolo-
gies causing hepatitis is broad and comprises of infectious
agents, mainly hepatotropic but also other viruses [2–4],
bacteria, protozoa, autoimmunity, chronic cholestatic dis-
eases like autoimmune hepatitis (AIH) [5], primary bili-
ary cirrhosis (PBC) [6] and primary sclerosing cholangitis
(PSC), metabolic diseases (e.g. Wilson’s disease), a pleth-
ora of nutritive-toxic insults including alcohol abuse [7],
non-alcoholic fatty liver disease (NAFLD), and various
drugs [8]. A common feature of hepatitis is the presence of
inflammatory cells and damage of liver tissue.
Characteristic histological features of acute hepatitis in-
clude inflammatory cells in portal tracts and within the
parenchyma, focal or zonal necrosis, dying hepatocytes
(acidophilic bodies, apoptotic cells), resulting in architec-
tural disarray and cholestasis [1]. With disease progression,
features of resolution become visible including the appear-
ance of pigment-laden macrophages and signs of regener-
ation. The degree to which the individual features can be
observed varies and depends on the underlying disease and
clinical setting.
Chronic hepatitis is characterised by the persistence of in-
flammatory cells and the destruction of liver cells. Again,
morphologic patterns among chronic hepatitis of diverse
aetiologies are not uniform, but pathognomonic or char-
acteristic features exist. For example, the presence of so-
called ground glass hepatocytes (i.e., granular eosinophilic)
staining due to abundant hepatitis B antigens (HBsAg) in
the endoplasmic reticulum of hepatocytes indicates chronic
hepatitis B infection (figure 1A). The presence of inflam-
matory activity in the interphase between portal tract and
lobules with numerous plasma cells is characteristic of AIH
(figure 1B).
Remarkably, the liver has a unique regenerative capacity
and can replace a significant loss of liver cells by starting
a programme of compensatory proliferation, driving hep-
atocytes from a resting G0 to a replicative G1 state [9].
However, chronic liver damage and regeneration results in
“scarring” of the liver: A typical sequela of chronic hepat-
itis is the development of liver fibrosis (i.e., the deposition
of excessive fibrous tissue [10]). The location of fibrosis
also varies depending on the aetiology and duration of liver
disease. Fibrosis may proceed such that normal lobules
are replaced by architecturally abnormal nodules, resulting
mainly from regenerative hyperplasia, separated by fibrous
tissue. At this point, the late stage of progressive fibrosis,
called cirrhosis, has developed which is generally regarded
as irreversible. Patients with cirrhosis are prone to a variety
of complications and have a reduced life expectancy. De-
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compensated cirrhosis is characterised by life-threatening
complications. Another complication of cirrhosis is the de-
velopment of hepatocellular carcinoma (HCC). HCC de-
velop in the background of cirrhosis of almost any cause,
including AIH [11] and PBC [12]. In contrast to a hepatitis
B carrier state, cirrhotic transformation of the liver seems
to be required for development of HCC in both AIH and
PBC.
Chronic inflammation – a state whichfosters multiple hallmark functions ofcancer
When Rudolph Virchow presented his concept of tumour
development in a lecture series on “Die krankhaften
Geschwülste”, he postulated a link between wound healing,
scar formation, inflammation and the development of tu-
mours [13, 14]. His speculation on the existence of a
cancer-bacillus was even more remarkable at that time, es-
pecially as we know today that he was correct [14, 15].
In the last 25 years, numerous clinical and epidemiological
studies have corroborated the link between chronic inflam-
mation and carcinogenesis [16]. These studies have demon-
strated without any doubt that chronic inflammation pro-
motes the risk for cancer development. Consequently, the
“inflammatory microenvironment” was added as the sev-
enth hallmark of cancer complementing the list of hall-
marks published in a seminal review in 2000 [15, 17, 18]
which included: (1) sustained proliferative signalling, (2)
evading growth suppressors, (3) resisting cell death, (4)
enabling replicative immortality, (5) inducing angiogen-
esis, and (6) activating invasion and metastasis [15]. Re-
cently, this list was updated by adding reprogramming of
energy metabolism and evading immune destruction as fur-
ther conceptual hallmarks [19].
Chronic inflammation can be induced by viruses, for ex-
ample hepatitis B and C viruses (HBV, HCV), which fur-
ther trigger HCC development [20]. Infection with patho-
genic bacteria (e.g., Helicobacter pylori) promotes gastritis
and increases the risk for gastric cancer and mucosa-asso-
ciated lymphoid tissue (MALT) lymphoma [21]. Infection
with parasites (e.g. Schistosoma) causes chronic inflam-
mation potentially leading to bladder, liver or colorectal
cancer [22]. Moreover, as noted above, autoimmune dis-
eases can trigger cancer development: Autoimmune hepat-
itis increases the risk for HCC development [23], and in-
flammatory bowel diseases (e.g., ulcerative colitis, Crohn’s
disease) are a predisposition to colon cancer formation
[24]. Besides, PSC can lead to cholangiocellular carcinoma
(CCC) [25]. In addition to infectious and autoimmune dis-
orders, chronic or acute intoxication (e.g., alcohol, drug
abuse, aflatoxin-b) can cause inflammation-induced carci-
nogenesis [26]. Only recently dietary and genetic obesity
were also shown to promote hepatitis and tumourigenesis
[27, 28].
However, numerous clinical reports and experimental data
support the idea that inflammation (acute or chronic) can
also be anti-carcinogenic [29-32]. This was already noted
by the oncologist William Coley who used concomitant ac-
tivation of the adaptive immune system (e.g., by injection
of dead bacteria Streptococcus pyogenes, Serratia marces-
cens and active endotoxins) to treat cancer patients [33].
Most likely the hereby induced inflammation activates the
innate and adaptive immune cells to trigger destruction of
tumour cells. Today this therapeutic concept is used to treat
bladder cancer [34].
Although immense progress has been made in the past to
understand the mechanism(s) by which chronic inflamma-
tion influences tissue integrity, chromosomal stability, ap-
optosis, proliferation and cancer development, the exact
pathways and cellular ingredients that define inflammation
as anti- or pro-carcinogenic remain unknown. The initial
composition of immune cells in the target organ, the cells
infiltrating or surrounding tumour tissue, the interaction of
the tumour stroma with immune cells, the expression of
cytokines and chemokines and the organ in which chronic
inflammation occurs might explain why inflammation is a
double- edged sword [15, 19, 29, 35]. Furthermore, it re-
mains elusive if the transition from chronic inflammation
to cancer underlies specific pathways or if the existence
of an inflammatory environment unspecifically increases
the stochastic likelihood to cause cancer. Presumably, both
scenarios are possible depending on various genetic host
factors and the aetiology driving cancer.
Figure 1
Histology of various human liver diseases. (A) Histology of
chronic hepatitis B infection. Chronic inflammation of mild
activity mainly confined to the portal tract (left) and numerous
hepatocytes with ground class cytoplasm (arrows) due to
accumulation of viral proteins (HBsAg) (haematoxylin and
eosion staining). (B) Histology of autoimmune hepatitis (AIH).
Histology reveals portal and interphase inflammatory activity and
numerous plasma cells (right). Note the presence of several
apoptotic hepatocytes (arrows) (haematoxylin and eosion
staining). (C) Histology of cirrhotic liver tissue. Cirrhosis is
characterised by architecturally abnormal nodules of liver tissue,
separated by fibrous tissue (red, elastica van Gieson staining)
(D) Histology of hepatocellular carcinoma (left) adjacent to
cirrhotic liver tissue (right). Note the inflammatory infiltrate at the
border between the tumour and surrounding tissue
(haematoxylin and eosion staining).
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Hepatocellular carcinoma (HCC)
Today, HCC is the third most common cause for cancer-
related death world-wide [36]. In some African and Asian
countries HCC has become the most prevalent cause for
cancer-related death [37]. Given the effort invested in the
past, the clinical success to pharmacologically treat HCC
patients has been limited. Currently, liver transplantation
is the most effective way to prolong the life of HCC pa-
tients [38]. However, new drugs are being generated and
investigated. Recently, various inhibitor molecules have
entered clinical practice. As such, Sorafenib (Nexavar®) is
one of the new therapeutic agents inhibiting pro-angiogen-
ic and tumourigenic receptor tyrosine kinases (e.g., c-Kit;
VEGFR-1, -2, -3; PDGFR-β). Its efficacy in the context
of HCC treatment was demonstrated in two large phase III
clinical trials [39, 40]. In addition, other therapeutics, such
as Regorafenib (BAY 73-4506), are being investigated for
their potential as anti-tumour regimens.
Although these regimens successfully prolong patient sur-
vival, their effect is limited and treatment is rather palli-
ative [39, 40]. Furthermore, since HCC do not resemble a
single entity but rather a diverse spectrum of cancers, vari-
ous therapeutic approaches might be needed to treat HCC
subtypes. Due to the outlined problems, a systemic thera-
peutic approach to treat liver cancer is not available, under-
lining the need for new targets to be investigated in basic
and clinical research.
The most common cause for chronic hepatic inflammation
in humans is infection with HBV or HCV [41]. The spread
of HBV and HCV has resulted in approximately 500 mil-
lion people with persistent virus infections [41], some of
which will lead to liver cancer causing the strong rise in
HCC incidence. At the same time, eradication of these
chronic viral infections has turned out to be very ineffective
[42].
Therefore, analysis and identification of fundamental in-
flammatory signalling pathways causing the transition
from chronic liver injury to dysplasia and HCC could de-
pict a plethora of new targets or predictive markers to
identify and treat patients with chronic liver inflammation.
Of highest importance will be the identification of path-
ways that stabilise liver tumourigenesis, as not all HCC de-
pend on an inflammatory environment and therefore may
not respond to an anti-inflammatory therapy.
From mice to men: A difficult task
In light of the above information, modelling liver cancer in
animals appears to be crucial especially to determine which
mouse models exist and what human pathology they re-
flect. Indeed, establishment of mouse models that mimic
particular pathological aspects of liver tumourigenesis in
humans can “only” be the initial step. It should be followed
by a detailed analysis of the pathways that the particular
model relies on. Furthermore, knowledge of which specific
pathological features of human HCC subtypes the mouse
model represents may increase the efficacy of clinical trials
in the future.
The link between chronic inflammation preceding fibrosis
and liver cancer has been recapitulated in rodent models
[19, 43]. In the last 20 years, a huge amount of rodent mod-
els of chronic or acute liver damage-induced carcinogenes-
is (e.g., chemically, metabolically or genetically) have been
established. Some of the most important ones are discussed
in this review (see also table 1).
The TgAlb-1, HBV mouse model
In an elegant study, the pathogenetic mechanisms respons-
ible for HCC formation during chronic HBV infection were
investigated [44]. Using transgenic mice which expressed
the HBV surface antigen (HBsAg) but which were immun-
ologically tolerant to HBsAg at the T-cell level, the au-
thors investigated how a chronic immune response against
a viral antigen drives inflammation and HCC formation
[44]. TgAlb-1, HBV mice, which were thymectomised, ir-
radiated, bone marrow-reconstituted and adoptively trans-
ferred with HBsAg-specific CTLs, developed a severe
MHC class I-restricted necroinflammatory liver disease.
Importantly, it was shown that this chronic immunemedi-
ated liver cell injury triggers HCC development even in
the absence of viral transactivation, insertional mutagenes-
is, and genotoxic chemicals [44]. This model shows that
chronic inflammation induces liver cancer, thereby recapit-
ulating one important aspect of virus-induced chronic hep-
atitis and liver cancer formation in humans. Some of the
most important mouse models for HBV- or HCV- induced
liver cancer formation and their underlying mechanisms
are listed in table 1.
Chemically induced HCC – the DENmouse model
The most intensively studied model of chemically induced
liver cancer development is the use of diethylnitrosamine
(DEN), both in rats and mice [32, 45]. In mice, a single
injection of DEN in 2-week-old animals leads to acute
hepatitis, a pronounced Kupffer cell response, hepatocyte
proliferation and DNA damage, finally leading to HCC
at approximately 8 to 10 months of age [32]. Treatment
with DEN has several advantages: (a) DEN can be used in
mice of various genetic backgrounds, (b) DEN treatment
induces high HCC incidence, and (c) it is highly repro-
ducible. In addition, HCC in DEN- treated mice recapitu-
lates one important feature of carcinogenesis: metastasis.
However, the major event in DEN-induced hepatocarcino-
genesis is the induction of mutations and a strong pro-pro-
liferative environment in a previously healthy liver. Al-
though this occurs concomitantly with acute liver damage,
the sequence of primary DNA damage followed by in-
flammation and Kupffer cell activation does not necessar-
ily mimic the chain of events of an inflammation-induced
paradigm. Nevertheless, DEN treatment has depicted im-
portant molecular and cellular pathways involved in HCC
development (e.g., Stat-3P; IL6) and can be used to identi-
fy new targets in order to block chemically induced liver
carcinogenesis in humans [32, 46].
Additionally to DEN, several other chemical carcinogens
such as a aflatoxin B1 (AFB) or choline-deficient diet have
been used to initiate HCC development in mice (table 1).
AFB is of particular interest because of its contribution to
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the high rates of HCC in China and Western Africa [47,
48].
The mdr2-ko mouse model
The mdr2-knockout mouse model embodies the prototype
of a defined genetic modification leading to chronic in-
flammation and liver cancer. It is used to classify the path-
ways involved in chronic inflammation-induced HCC
formation [49]. Deficiency of the multi-drug resistance
gene 2 (mdr2), a biliary transporter protein, causes cho-
lestatic hepatitis and liver cancer [49]. Mdr2 deficiency
induces different subsequent phases: cholestasis, inflam-
mation, dysplasia, dysplastic nodules, carcinoma and meta-
stasis, recapitulating aspects of inflammation-induced car-
cinogenesis in humans. The cholestatic and inflammatory
state triggers hepatocyte-derived NF-kb through TNF up-
regulation in adjacent endothelial and inflammatory cells
[49]. Turning off NF-κb in mdr2-ko hepatocytes did not
affect liver cancer development nor early phases of hep-
atocyte transformation [49]. NF-κb inhibition by anti-TNF
treatment – even at the late stage of tumourigenesis – res-
Table 1
Frequently used HCC mouse models. Many different mouse models have been established in the past 30 years. Some of the most frequently used are listed below. Due to
space limitations we were not able to list all HCC models available.
Models Phenotype Known mechanism References
Transgenic models
AlbLTαβ Chronic inflammation, fibrosis, dysplasia, HCC at
12 mo
Chronic hepatitis, cell damage, apoptosis, compensatory hepatocyte
proliferation, genomic instability
[53]
Alb-c-myc Dysplasia, preneoplastic foci, adenoma, HCC at
12–15 mo
Apoptosis induction, enhanced proliferation, genomic instability [73]
c-myc/TGFα Dysplastic and apoptotic changes in hepatocytes
multiple focal lesions, HCC at 8 mo
Acceleration of neoplastic development compared to single- transgenic
models
[69, 74]
MT-TGF-α Higher DNA content, dysplastic hepatocytes,
adenmoas and HCC at 12 mo
Mitogenic effect due to chronic exposure to high levels of TNFα [75, 76]
Transgenic models / viral genes
c-myc/HBX Expansion of hepatic lobules, dysplastic foci,
neoplastic nodules, HCC at 6–8 mo
2-fold higher hepatocyte proliferation rate compared to c-myc-only
transgenic mice
[71, 77]
HBV large envelope protein Inflammation, regenerative hyperplasia,
aneuploidy, HCC at 15 mo
Accumulation of HBsAg in the ER leading to hepatocyte death [78]
HBV X protein Cytoplasmic vacuolations, neoplastic lesions,
HCC at 13 mo
Transcriptional transactivation of viral genes leading to alter host gene
expression and carcinomas
[79]
HCV core Steatosis, HCC at 16 mo Core protein acts as transcriptional activator affecting the proliferative
ability of hepatocytes, ROS production, transcriptional activation of
TNF and IL1
[80]
SV40 T-Ag Hyperplastic hepatocytes, dysplasia, HCC at 3
mo, lung metastasis
SV40 T-Ag-mediated immortalisation, cell transformation, aberrant
DNA replication
[81, 82]
TgAlb-1/HBV Inflammatory infiltrates, focal hepatocellular
necrosis, disorganisation of lobular architecture,
HCC at 17 mo
Expression of HBsAg in hepatocytes – HBsAg-tolerant mice – HCC
formation due to CTL mediated cell damage
[44]
Knockout models
Dicer1Δhep Depletion of glycogen storage, steatosis, HCC at
12 mo
Impaired lipid and glucose metabolism, increased expression of cell
cycle promoting genes, increased proliferation and apoptosis
[72]
MCL-1Δhep Apoptoses, architectural disarray, fibrosis,
dysplastic nodules and HCC at 8 mo
Spontaneous hepatocyte apoptosis leading to chronic liver damage
and compensatory proliferation
[60, 61]
MCL-1Δhep/p53-/- More severe liver damage and higher tumour
incidence compared to MCL-1Dhep
p53 inhibits apoptotic effectors and is known to interact with MCL-1 [62]
Mdr2-/- Cholastasis, inflammation, dysplasia, dysplastic
nodules, HCC at 10 mo, metastasis
Mice are unable to secrete phospholipids into bile leading to liver
disease
[49, 83]
Mst1/2-/- Loss of hepatocyte quiescence leading to
overgrowth
HCC at 3 mo
Mst1/2 deficiency leads to resistance to Fas-induced apoptosis and
loss of Yap1 phosporylation
[65]
NEMOLPC-KO Steatohepatitis, liver fibrosis, dysplasia, HCC at
11 mo
Increased apoptotic hepatocyte death and subsequent compensatory
proliferation
[58]
TAK1LPC-KO Steatohepatitis, liver fibrosis, dysplasia, biliary
cirrhosis, HCC at 4 mo
TAK1 deficiency leads to caspase-3- mediated apoptosis accompanied
by enhanced liver cell proliferation
[59]
Chemically-induced models
Aflatoxin B1 HCC at 11 mo – incidence rate depends on the
mouse strain
Chromosomal aberrations, sister chromatide exchange, chromosomal
strand breaks, uncontrolled DNA synthesis
[84, 85]
Choline deficient diet Steatosis, HCC at 11–12 mo Formation of oval cells due to oxidative DNA damage and
chromosomal instability finally leading to generation of hepatocytes
[86]
DEN wild-type
DEN IKKβΔhep
Acute hepatitis, hepatocyte proliferation, HCC at
8–10 mo, metastasis
3-fold higher tumour number compared to wt
Chemically induced DNA damage leading to genetic mutations
Increased ROS production and JNK activation, augmented hepatocyte
turn-over compared to wt
[51]
Transplantation models
Metastatic HCC xenografts
(LCI-D20)
100% lung metastasis incidence after 15 days Orthotopic implantation of metastatic tumour tissues [87]
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ulted in apoptosis of transformed hepatocytes and blocked
hepatocarcinogenesis. Therefore, NF-κb signalling might
be a pro-carcinogenic factor representing a possible target
for anti-tumour therapy.
The NF-κB pathway controls transcription of inflammat-
ory, pro-proliferative and anti-apoptotic genes [29] and is
one of the most important and best-studied inflammatory
signalling cascades [50]. Activation of NF-κB is documen-
ted by phosphorylation of the I-kappa-B kinase (IKK) com-
plex, consisting of two catalytic subunits, IKKα and IKKβ,
and a regulatory subunit called IKKγ. Upon recruitment of
adaptor proteins (e.g., TRAF2; RIP1) and activation by the
TGFβ-activated kinase 1 (TAK1), phosphorylation of the
inhibitory protein IκBα occurs and nuclear translocation of
NF-kB is initiated [31, 43]. However, NF-κB signalling is
complex, as exemplified by the DEN model: Hepatocyte-
specific deletion of IKKβ leads to increased HCC forma-
tion [51], suggesting an anti-tumourigenic role of IKKβ –
which is in contrast to data from mdr2-ko mice. However,
whether or not depletion of IKKβ alone changes the beha-
viour of the remaining IKK complex to solely drive carci-
nogenesis remains elusive.
The AlbLTαβ mouse model
Lymphotoxin (LT) acts directly on hepatocytes which ex-
press high levels of LTβR but little LT [52, 53]. T-cell-
derived LT and LIGHT signalling to hepatocytes controls
lipoprotein homoeostasis [54]. Moreover, LTbR signalling
is important for liver regeneration through T-cell-derived
LT expression [55] and LTβR signalling regulates hepatic
stellate cell function and wound healing [56].
We recently showed that LTα, β and their receptor (LTbR)
are increased in intrahepatic lymphocytes and hepatocytes
of patients with HBV- or HCV-induced chronic hepatitis or
HCC [53]. Various other liver diseases of non-viral aeti-
ology have shown significantly lower levels of LTα, β and
LTβR mRNA expression [35, 53].
Thus, the question remained whether LT expression in
mice suffices to induce liver inflammation and HCC.
Indeed, transgenic expression of LT specifically in the liver
recapitulated some features of human pathology seen in pa-
tients with chronic hepatitis B or C. AlbLTαβ mice deve-
loped hepatitis and HCC (figure 2). Furthermore, suppres-
sion of LTβR signalling reduced the incidence of chronic
hepatitis and abolished liver cancer development [57].
IKKβ’s role in tumour-promotion was recapitulated in Al-
bLTαβ mice backcrossed to IKKβΔhep mice [57]. In contrast
to the mdr2-ko mouse model, liver tumour formation in Al-
bLTαβ mice also occurred in the absence of TNFR1 [49,
57].
How can the contradictory role of IKKβ signalling be re-
conciled, when comparing the DEN, mdr2-ko and Al-
bLTαβ models in HCC formation? IKKβ signalling is cru-
cial for hepatocytes to respond to and survive acute liver
injury and DEN exposure. In its absence, the amount of
damaged and proliferative hepatocytes is increased leading
to a rise in HCC development. IKKβ signalling enables loc-
al chemokine expression by hepatocytes, – as known from
humans with chronic hepatitis C –, subsequently leading
to chronic inflammation and HCC. Consistently, AlbLTαβ
mice that lack B- and T-cells (AlbLTαβ Rag1–/–) also lack
chronic hepatitis and HCC [49]. In summary, the role of
NF-κB signalling in hepatocarcinogenesis might depend on
the model and the type or degree of liver inflammation and
injury [29, 32, 50].
The NEMO and the TAK1 mouse model
The role of NF-κB in hepatocarcinogenesis was further in-
vestigated by studying NEMO and TAK1 [58, 59]. Both
molecules control activation of NF-κB in various cellular
systems and mediate inflammatory signalling pathways
Figure 2
Chronic inflammation-induced liver damage and HCC in AlbLTαβ
mice. (A) Immunohistochemistry of representative livers from
9-months-old C57BL/6 and AlbLTαβ mice. B220+ B cells, CD3+
T cells, F4/80+ macrophages, Kupffer cells (scale bar: 150 μm).
Ki67+, proliferating hepatocytes (arrowheads) or inflammatory
cells are indicated (scale bar: 50 μm). (B, left two panels)
Macroscopy of C57BL/6 and AlbLTαβ livers. White arrows
indicate tumour nodules. White arrowhead indicates a complete
liver lobe affected by HCC. (B, right four panels) Liver histology
of 12-month-old C57BL/6 and AlbLTαβ mice. Collagen IV
staining highlights the broadening of the liver cell cords, loss of
collagen IV networks indicate HCC (scale bar: 200 μm). High
numbers of Ki67+ proliferating hepatocytes (arrowheads) in
AlbLTαβ HCC (scale bar: 100 μm). (C) Scheme of chronic
inflammation-induced liver carcinogenesis in AlbLTαβ mice.
Hepatocytes (brown) express LTα, LTβ and induce chemokine production (e.g., CCL2, CCL7, CXCL1, CXCL10) in the presence of IKKβ and
intrahepatic lymphocytes. Chemoattraction, activation of myeloid cells and lymphocytes expressing chemokine receptors (e.g., CXCR3,
CXCR2, CCR2, CCR1) causes hepatitis. Activated, infiltrating immune cells secrete cytotoxic cytokines (e.g., IL6, IL1β, TNFα, IFNγ, LTaβ)
causing tissue destruction, hepatocyte proliferation, cell death and tissue remodelling. Tissue destruction and remodelling supports the
infiltration of activated inflammatory cells (e.g., myeloid cells) leading to a feed-forward loop towards chronic aggressive hepatitis and HCC. *
Genetic depletion of components (IKKb; T and B cells) which leads to a block in chronic hepatitis and HCC development. Blocking LTβR
signalling with LTbR-Ig in 9-month-old AlbLTαβ mice reduces chronic hepatitis incidence and prevents HCC. RelA is schematically depicted as
a green circle, inducing transcription of NF-κB target genes (arrow). B and T: B and T cells; MØ: macrophages; N: neutrophils; NK: NK cells.
Adapted from Haybaeck et al., Cancer Cell, 2009.
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[32]. Conditional deletion of NEMO or TAK1 in hepato-
cytes causes spontaneous HCC development; however, liv-
er carcinogenesis was much more aggressive and also co-
incided with biliary ductopenia and cholestasis in the latter
[59]. This suggests that members of the NF-κB signalling
pathway possess a tumour preventing capacity. However,
the role of NF-κB signalling in HCC formation is probably
more complex, taking into account that the early onset of
biliary cirrhosis and hepatocarcingenesis in TAK1Δhep mice
can be prevented following backcrossing to NEMOΔhep
mice [59]. Therefore, NEMO is strongly involved in the
highly aggressive phenotype of TAK1Δhep mice in the ab-
sence of NF-κb signalling. It is currently unclear if and how
these new genetic tumour models recapitulate an entity of
human HCC, and future studies are needed [31, 43].
A model for apoptosis andproliferation induced HCC: theMcl-1Δhep mouse
Regulation of tissue homoeostasis is essential for main-
taining liver function. A tightly controlled network of pro-
and anti-apoptotic factors is crucial to regulate liver tissue
development and homoeostasis by sensing extrinsic or in-
trinsic death signals, subsequently inducing apoptosis to re-
move damaged hepatocytes and protect cells against malig-
nant transformation. Anti-apoptotic family members (e.g.,
Bcl-xL, Bcl-2, Mcl-1) interact with pro-apoptotic members
(e.g., Bax, Bad) to inhibit the permeabilisation of the mi-
tochondrial membrane. It was found that hepatocyte-spe-
cific knock-out of Mcl-1 affected liver tissue homoeostasis
and increased the sensitivity of hepatocytes towards apop-
tosis [60]. Increased apoptosis of hepatocytes in Mcl-1Δhep
mice resulted in chronic liver damage, compensatory hep-
atocyte proliferation, liver fibrosis and finally HCC form-
ation [61] (fig. 3). Tumours revealed a heterogeneous pat-
tern ranging from small dysplastic nodules to HCC. The
neoplastic nature of tumours was confirmed by the expres-
sion of HCC markers (e.g., gluthamine synthetase) and by
chromosomal aberrations [61].
A second study confirmed the link between enhanced hep-
atocyte apoptosis and tumourigenesis in Mcl-1Δhep mice.
Backcrossing of Mcl-1Δhep to p53–/– mice was performed to
examine whether the tumour-suppressor p53 plays a role in
the induction of spontaneous apoptosis in Mcl-1- deficient
hepatocytes [62]. The authors found a high susceptibility of
Mcl-1Δhep and p53–/– double knock-out mice (DKO mice)
to neonatal death (60%), whereas surviving DKO mice dis-
played more severe liver damage and a higher tumour in-
cidence. In this model, the loss of p53 promoted liver tu-
mour development due to the multi-faceted role of p53 in
apoptosis [62]. p53 is known to bind and inhibit the ap-
optotic effectors Bak and Bim, as well as to interact with
Mcl-1 [63]. Thus, increased liver damage in DKO mice is
not surprising when an additional key player in the negat-
ive regulation of apoptosis is removed.
In summary, both studies of Mcl-1Δhep mouse models de-
scribe the close relationship between a constant loss of
liver cells triggered by apoptotic stimuli in correlation with
chronic liver injury and spontaneous tumour formation.
This sequence recapitulates central aspects of human dis-
eases like chronic hepatitis C [64].
The Mst1/2 knock-out model
In another knock-out mouse model, germline deletions of
the protein kinases Mst1 and 2, the mammalian homo-
logues of the Drosophila Hippo kinase, were generated
[65]. Loss of function of Hippo accelerates cell cycle pro-
gression as shown in Drosophila melanogaster [66, 67].
Zhou et al. showed that Mst1 and Mst2 inhibit the kinase
Yes associated protein 1 (Yap1), in order to suppress HCC
formation [65]. Remarkably, the Mst-YAP1 pathway is also
disrupted in several human HCC [65].
The c-myc/TGFα transgenic mousemodel
In 1986 it was shown that hepatitis virus infected wood-
chucks displayed rearrangement and enhanced expression
of the oncogene c-myc in HCC [68]. In addition, the group
of Snorri Thorgeirsson demonstrated that co-expression of
c-myc and TGFα in mouse livers led to a rise in HCC com-
pared to the expression of either of these transgenes alone
Figure 3
Enhanced proliferation and liver cell damage in Mcl-1Δhep mice.
(A) Immunohistochemical analysis of proliferating hepatocytes
stained for Ki67. A strong increase in proliferating hepatocytes is
found in Mcl-1Δhep mice compared to wild-type mice. (B) Liver
damage is assayed by analysis of serum amino transferase
levels. In comparison to wild-type mice, Mcl-1Δhep mice display a
strong increase in AST and ALT (not shown) levels at early
(1–2 months) and later stage (12 months). (C, left two panels)
Macroscopic pictures of HCC in Mcl-1Δhep mice. * statistically
significant; n.s.: not significant. (C, right four panels) Histological
analysis of C57BL/6 and Mcl-1Δhep livers. Collagen IV staining
highlights the broadening of the liver cell cords, loss of collagen
IV networks indicate HCC (scale bar: 200 μm). High numbers of
Ki67+ proliferating hepatocytes, positivity for glutamine
syntethase and loss of reticulin fibres (Gomori staining) indicate
the presence of HCC. (D) Schematic model explaining the
hypersensitivity of Mcl-1Δhep mice to stress-induced apoptosis
and its effects on liver homeostasis. Adapted from Weber et al., Hepatology, 2010.
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[69, 70]. Although morphological similarities were found
between the two transgenic lines, the dramatic acceleration,
extent and severity of hepatic lesions in c-myc/TGFα mice
showed a synergistic effect of c-myc and TGFα [69, 70].
Furthermore, the HBV X gene potentiates c-myc-induced
liver oncogenesis in transgenic mice [71]. These transgen-
ic models turned out to be extremely useful to identify
oncogene-dependent signalling pathways in human HCC.
Liver-specific Dicer knock-out mice
There is a plethora of publications that indicate that viral
infection is correlated with a deregulation of micro-RNAs,
and growing evidence suggests that micro-RNAs coordin-
ate various biological processes in the liver [72]. Using a
conditional knock-out mouse model with Dicer disrupted
specifically in hepatocytes, an enzyme essential for the
processing of micro-RNAs, Sekine et al. investigated the
consequences of loss of micro-RNAs [72]. Unexpectedly,
mice with hepatocytes deficient in Dicer displayed promin-
ent steatosis and depletion of glycogen storage [72]. Dicer
elimination resulted in both increased hepatocyte prolifera-
tion as well as strong apoptosis. Over time, Dicer-express-
ing wild-type hepatocytes which had escaped Cre-mediated
recombination progressively repopulated the entire liver.
Unexpectedly, two thirds of the mutant mice spontaneously
developed HCC derived from residual Dicer-deficient hep-
atocytes at 1 year of age. Therefore, micro-RNAs control
liver homoeostasis and HCC formation.
Xenotransplantation of human livertissue
Xenotransplantation of human liver cancer tissue into
immuno-compromised mice made it possible to investigate
the efficacy and pharmacokinetics of various antitumor re-
gimens, as well as to investigate signalling mechanisms
driving or preventing liver carcinogenesis or metastasis
[87]. Tumours can be grafted but can also be established
by injection of human cancer cells either subcutaneously
(ectopic model) or intrahepatically (orthopic model). Tu-
mour development is rapid and highly reproducible in vari-
ous xenograft models; however, it is noteworthy that they
often show only minor similarities to human tumours.
Summary
Hepatitis can be elicited in response to a plethora of diverse
insults to the liver. Chronic inflammation is associated with
persistent liver damage and consecutive regeneration, po-
tentially leading to fibrosis and cirrhosis and the develop-
ment of HCC. Human HCC, even of the same aetiology,
reveal a broad clinical, morphological and molecular spec-
trum, however, they generally have a bad prognosis. The
efficiency of drugs is currently limited, but might be im-
proved by the identification of specific molecular targets.
Several mouse models are available which are used to re-
capitulate different aetiologies of human hepatocarcino-
genesis. It is now of paramount importance to determine
how these models are transferable to human HCC and how
they can be thus exploited for interventional studies.
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